The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

Other criteria

• Between 18 and 55-years-old
• BMI between 18 and 35 kg/m2
• Score a 2 or above on the Adult ADHD Self-Report Scale (ASRS) Symptom Checklist Part A or have an official ADHD diagnosis
• Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND
• Are not pregnant or currently breastfeeding
• Have no history of significant allergic condition, hypersensitivity, or allergic reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint
• Have not used CBG or any other cannabinoid products in the past 30 days
• Willing to abstain from using cannabis or any THC-containing product for the duration of the study
• Have never used a synthetic cannabinoid or cannabinoid analogue (e.g., dronabinol, nabilone), or a synthetic cannabinoid receptor agonist (e.g., spice, k2)
• Have not been exposed to any investigational drug or device 30 days prior to screening and you have no plans to take an investigational drug during the study
• Willing to maintain a stable treatment regimen (i.e., no change in current medication use) for the duration of the study
• Not currently taking a prescription medication for ADHD and have not been prescribed a medication for ADHD in the past six months
• Not currently having thoughts of committing suicide
• Does not meet criteria for current severe major depressive disorder or a substance use disorder
• Have not been diagnosed with bipolar disorder or psychosis
• Do not have an acute illness, such as a respiratory infection or other illness that would interfere with study participation; not currently taking medication for an acute illness (e.g., antibiotic)
• Do not have history of diagnosis related to liver function and/or significantly impaired liver function (e.g., cirrhosis of the liver, hepatitis)
• Willing to ensure they have used effective contraception (for example, oral contraception, double barrier, intra-uterine device) for 30 prior to the study and for 30 days after study completion
• Have access to a ride to the University of Arkansas campus for research appointments
• Willing to comply with current university mandates as they pertain to COVID-19 protocols (e.g., mask wearing)
• Do not have any serious or unstable physical health conditions including neurological or renal illness
• Do not have any current or historical cardiovascular conditions, including hypotension, bradycardia, or heart block
• No atrial fibrillation, bradycardia, or tachycardia detected via mobile electrocardiogram during the in-laboratory visit
• No recent illicit drug use other than cannabis, or alcohol use in the 12 hours preceding the in-laboratory visit
• Not currently prescribed or taking the following medications:; Warfarin; Clobazam; Valproic acid; Phenobarbital; Mechanistic Target of Rapamycin [mTOR] Inhibitors; Oral tacrolimus; St. John's wort; Epidiolex; Escitalopram; Cardiovascular medications; Strong CYP3A4 inhibitors (e.g., ketoconazole)